Regulus Therapeutics Inc.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat various diseases. The company's product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for Alport syndrome, and RGLS8429, an anti-miR targeting miR-17 in Phase 1b clinical study for autosomal dominant polycystic kidney disease. Additionally, Regulus is developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

Products

• RG-012 for Alport syndrome

• RGLS8429 for autosomal dominant polycystic kidney disease

• Preclinical drug products for target organ-selective delivery strategies